Microglia demonstrate local mixed inflammation and a defined morphological shift in an APP/PS1 mouse model by Holloway, OG et al.
Un
co
rre
cte
d A
uth
or
 P
ro
of
Journal of Alzheimer’s Disease xx (2020) x–xx
DOI 10.3233/JAD-200098
IOS Press
1
Microglia Demonstrate Local Mixed
Inflammation and a Defined Morphological
Shift in an APP/PS1 Mouse Model
1
2
3
Olivia G. Holloway, Anna E. King and Jenna M. Ziebell∗4
Wicking Dementia Research and Education Centre, College of Health and Medicine, University of Tasmania,
Tasmania, Australia
5
6
Handling Associate Editor: Zhou Wu7
Accepted 28 July 2020
Abstract.8
Background: Microglia are traditionally described as the immune cells of the brain and have an inflammatory role in
Alzheimer’s disease (AD). Microglial morphological and phenotypic shifts in AD have not been fully characterized; however,
microglia are often described as either pro- or anti-inflammatory.
9
10
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Objective: To determine microglial if microglial morphology and phenotype changes with disease status.12
Methods:This study observed morphology through Iba1 immunohistochemistry on tissue sections encompassing the primary
motor cortex and somatosensory barrel fields. Immunohistochemistry for pro-inflammatory markers: CD14 and CD40; and
anti-inflammatory markers: CD16 and TREM2, was performed at 3, 6, and 12 months of age which correlated with pre-plaque,
onset, and significant plaque load in APP/PS1 brains (n = 6) and compared to age-matched littermate controls (n = 6).
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Results:Microglia demonstrated a defined morphological shift with time. Deramified morphologies increased in the APP/PS1,
at both 6 months (p < 0.0001) and 12 months (p < 0.0001). At 12 months, there were significantly lower numbers of ramified
microglia (p < 0.001). Results indicated that microglia have a heterogenic marker immunoreactivity as CD16, TREM2, and
CD40 were associated with an activated morphology at the same time points. All inflammatory markers were significantly
upregulated at 12 months in the APP/PS1 mice (TREM2 (F(2,30) = 10.75, p = 0.0003), CD40 (F(2,30) = 15.86, p < 0.0001), CD14
(F(2,30) = 6.84, p = 0.0036), and CD16 (F(2,30) = 3.026, p = 0.0635)).
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Conclusion: Our data indicate that pro- and anti-inflammatory factors of microglia occur in APP/PS1 mice.23
Keywords: Alzheimer’s disease, anti-inflammatory, microglia, morphology, phenotype, pro-inflammatory
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INTRODUCTION25
Microglia are the resident immune cell of the26
brain. Microglia are integral in the mai tenance of27
the central nervous system (CNS), through functions28
of cellular debris clearance, synaptic maintenance,29
inflammation, and neuronal support [1]. In a healthy30
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brain, microglia respond to changes in the CNS 31
homeostasis with changes to their morphology and 32
the release of inflammatory cytokines to regain 33
homeostasis. This response may become undesir- 34
able in diseases concerning the CNS, as pathology 35
may elicit a chronic inflammatory response lead- 36
ing to more harm than benefit [2]. Uncertainty to 37
the exact role microglia have in disease is relevant 38
in the context of Alzheimer’s disease (AD), a neu- 39
rodegenerative disease, hallmarked by neurofibrillary 40
tangles and deposits of amyloid- (A) plaques. In 41
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AD, microglia are thought to lose their homeostatic42
function due to the ongoing insult of pathology, con-43
sequently driving disease progression [3, 4].44
Microglial inflammation in AD is considered detri-45
mental due to their inflammatory profiles being46
deemed predominantly pro-inflammatory. A multi-47
tude of markers have been ascribed to microglia48
in AD, including a variety of cluster of differenti-49
ation (CD) markers [1], chemokines and cytokines50
[2] and most recently the report of disease-associated51
microglia [3]. There is increasing evidence in other52
models of disease suggesting microglia display53
a mixed inflammatory phenotype [5, 6]. This aligns54
with an emerging hypothesis that microglial phe-55
notypes exist on a continuum between pro- and56
anti-inflammatory states [7, 8]. Morphologies have57
been hypothesized to indicate function or cell-surface58
marker expression (i.e., phenotype); however, few59
studies have investigated marker expression with a60
morphological analysis to determine whether this is61
the case in AD. Therefore, it is of interest to com-62
bine a phenotypic and morphological analysis in a63
model with a persistent inflammatory stimulus. To64
address this knowledge gap, we investigated the phe-65
notype of microglia and their morphology throughout66
disease progression via a subset of inflammatory sur-67
face markers (CD14, CD16, CD40, and TREM2).68
These markers have been reported to change in clin-69
ical cases of AD [4–6] and in the instance of CD1470
murine studies have indicated integral roles in medi-71
ating the inflammatory cascades but also amyloidosis72
[7]. This study combined an analytical approach in an73
AD mouse model (APP/PS1) characterized by A74
plaques.75
MATERIAL AND METHODS76
All experimental procedures were performed in77
accordance with the Australian Code of Practice78
for the Care and Use of Animals for Scientific79
Purposes and approved by the Animal Ethics Com-80
mittee of the University of Tasmania (A12780). A81
total of n = 36 mice were used in this study. Male82
transgenic APPswe, PSEN1dE9 (APP/PS1; n = 6 per83
timepoint) were used as a model of amyloidosis.84
These mice express mutant mouse/human amyloid85
precursor protein (APP) and mutant human prese-86
nilin 1 (PS1) on C57BL/6 background [B6.Cg-Tg87
(APPswe, PSEN1dE9) 85Dbo/J] (APP/PS1;(5). This88
model simulates A pathology that resembles the89
initial stages of AD, and A deposits have been90
observed from 3 months of age, with profuse plaque 91
deposition present by 8 months of age [8, 9]. Age- 92
matched wildtype littermate male mice served as 93
controls (n = 6/time point). Animals were housed in 94
standard conditions (20◦C, 12/12 h light/dark cycle) 95
with water and food ad libitum. 96
Tissue preparation 97
APP/PS1(TG) and age matched wildtype mice 98
(WT) were transcardially perfused with 4% 99
paraformaldehyde in PBS at 3, 6, or 12 months of 100
age. Brains were removed and post-fixed in 4% 101
paraformaldehyde in PBS. Tissue was cryoprotected 102
in sucrose, before being frozen. Brains were serially 103
sectioned in the coronal plane on a cryostat (Leica 104
CM 1850) at 40m. Sections used for analysis were 105
from bregma 2 mm to bregma –2.75 mm, according 106
to the mouse brain atlas [10]. All analyses were 107
performed blind to genotype and age. 108
Immunohistochemistry for microglia 109
For each animal, two sections were stained encom- 110
passing the regions of interests (ROI) primary motor 111
cortex and somatosensory barrel fields. These tis- 112
sue sections were labelled as described as below. 113
Microglial morphology was assessed by staining with 114
rabbit anti-Iba1 (1:1000, Wako, Cat: 019-19741). In 115
order to discriminate phenotype other known markers 116
of microglia were used in conjunction with Iba1: pro- 117
inflammatory markers; mouse anti-CD40 (1:1000, 118
ThermoFisher Scientific, Cat: 14-0402-82), mouse 119
anti-CD14 (1:500, Abcam, Cat: ab182032, and anti- 120
inflammatory markers; mouse anti-TREM2 (1:1000, 121
R&D systems, Cat: AF1729), and mouse anti-CD16 122
(1:500, ThermoFisher Scientific, Cat: MA1-7633). 123
Prior to primary antibody incubation, a blocking 124
solution of 4% milk was applied for 2 h. Follow- 125
ing overnight incubation with primary antibodies at 126
4◦C, sections were washed in PBS. Labelling was 127
visualized by species specific AlexaFluor secondary 128
antibodies for multiple labelling at 1:2000, incubated 129
for 2 h at room temperature (donkey anti-rabbit IgG- 130
594, Cat: 711-585-152, donkey anti-mouse IgG-488, 131
Cat: 715-545-150, donkey anti-sheep IgG-488, Cat: 132
713-545-147, or goat anti-rat IgG-488, Cat: 112- 133
545-167). Following secondary antibody incubation, 134
sections were washed in PBS. Amylo-Glo “ready to 135
dilute” (Biosensis) stain was used to visualize plaque 136
deposits as per manufacturer’s directions. Briefly, 137
following the secondary antibody incubation and 138
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subsequent washes, the tissue sections were placed139
into a 70% ethanol solution for 5 min at room temper-140
ature. The sections were then rinsed in MilliQ water141
for 2 min and placed in Amylo-Glo stain for 10 min.142
The sections were then rinsed in saline. The tissue143
sections were then rehydrated, rinsed in MilliQ, and144
mounted using Dako fluorescent mounting medium.145
Microscopy and image analysis146
Photomicrographs of the ROI were attained via a147
Perkin Elmer Ultra view VoX spinning disk confo-148
cal microscope and proprietary software. Microglial149
analysis was performed in Image J (v.1.41) using150
images with centered plaque deposits in the areas151
specified. Five images were analyzed for each ani-152
mal at each timepoint (3, 6, and 12 months, n = 6),153
totaling 30 images for each of the 6 cohorts. Microglia154
were counted using a grid on each image, each square155
was 70m2. Ten squares were chosen within each156
photomicrograph, 5 surrounding a plaque deposit157
and 5 on the edge away from the plaque. Analy-158
sis also considered microglia proximity to plaques.159
Microglia within a distance of one square (70m)160
were considered associated to plaques, and two161
squares away (140m) from the plaque was con-162
sidered non-associated with plaques. Iba-1 positive163
microglia were counted and identified into one of the164
five morphological categories; ramified, activated,165
hyper-ramified, rod, or amoeboid [11–17]. Following166
morphological analysis, microglia were examined167
for double-labelling of Iba-1 with either a pro-168
inflammatory phenotypic markers (CD14 and CD40)169
or anti-inflammatory phenotypic markers (CD16 and170
TREM2). Microglia were classified as having pos-171
itive colocalization through spatial overlap of Iba-1172
and the specified surface markers, which was verified173
through z-stacked images to identify fluorescently174
double-labelled microglia over 10m2 planes, allow-175
ing reduction of noise. The average number of176
microglial morphologies and the type of phenotypic177
immunoreactivity was recorded at each time point178
within both WT and Tg mice.179
Statistics180
Data were expressed as mean ± SEM and ana-181
lyzed with R stats software (version 1.1.463) and182
graphed though GraphPad Prism 5 software pack-183
age (GraphPad Software). Statistical significance was184
analyzed using Student t-test for two-group compari-185
son, followed by the Tukey post-hoc test for multiple186
comparisons. Differences were considered signifi- 187
cant for p < 0.05. 188
RESULTS 189
To further understand the relationship between the 190
morphological and phenotypic shifts of microglia, 191
we used an AD mouse model (APP/PS1) charac- 192
terized by A plaques. We did this by investigating 193
markers associated with pro- and anti-inflammatory 194
phenotypes and observed their corresponding mor- 195
phology to determine whether microglia present a 196
mixed or skewed inflammatory profile in response 197
to progressive plaque pathology and if morphol- 198
ogy has a specific inflammatory profile function. We 199
studied APP/PS1 mice and age-matched littermate 200
controls over three time points (3, 6, and 12 months), 201
correlating to progressive development of amyloid 202
plaques [8, 15, 18, 19]. This study quantified ramified, 203
activated/hyper-ramified and amoeboid/macrophage 204
microglia. Rod microglia were rarely present and 205
thus were not included in analysis. We set sig- 206
nificance at p < 0.05. Moreover, we performed a 207
spatial analysis of morphologies in regard to prox- 208
imity with plaque deposits. In both human and 209
mouse studies [20–24], ramified microglia are char- 210
acterized by symmetrically distributed thin, long 211
ramified processes with a small spherical soma. Acti- 212
vated microglia display significantly an enlarged 213
soma and processes with some retraction. Amoe- 214
boid microglia display an enlarged soma and lack 215
processes. 216
In Tg APP/PS1 mice, microglial morphology was 217
significantly altered compared to age-matched WT 218
controls. Ramified microglia, the surveying morphol- 219
ogy, demonstrated a significant decrease in number in 220
the Tg mice at 6 and 12 months, finding a significant 221
interaction between age and strain (F(2,30) = 19.75, 222
p < 0.0001; Fig. 1). Deramified microglia were found 223
to be significantly increased at 6 and 12 months 224
in the Tg mice relative to their WT counterparts, 225
with a significant interaction between age and strain 226
(F(2,30) = 24.92, p < 0.0001; Fig. 1). Similarly, the 227
fully deramified, amoeboid morphology was signifi- 228
cantly increased in the Tg mice at 6 and 12 months, 229
with a significant interaction between strain and age 230
(F(2,30) = 38.96, p < 0.0001; Fig. 1). Spatial analy- 231
sis of morphologies through Tukey’s post-hoc test, 232
revealed significance of the amoeboid morphology at 233
plaque location at 6 months (p < 0.05) and 12 months 234
(p < 0.0001) of age. 235
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Fig. 1. Distinct morphological shifts observed to increasing plaque load when comparing APP/PS1 (TG) and age-matched control (WT).
Quantification of the average number of ramified, activated and amoeboid microglia (+SEM) demonstrated a significant morphological shift
to increasing plaque pathology (D) when compared to their age-matched wildtype controls. Significant interaction between the age and
strain of mice was found for each morphology, (A) ramified; F(2,30) = 19.75, p < 0.0001, (B) activated; F(2,30) = 24.92, p < 0.0001, and (C)
amoeboid; F(2,30) = 38.96, p < 0.0001.
Pro-inflammatory markers CD14 and CD40236
were increased in transgenic mice237
CD14 is a lipopolysaccharide (LPS) receptor238
present as a membrane-bound form at the surface239
of myeloid cells. The interaction of LPS (endotoxin)240
with the CD14-TLR4 receptor complex modulates241
the host innate immune [25]. In the Tg APP/PS1242
mice, we hypothesized that CD14 immunoreactiv-243
ity would increase in activated microglia over time.244
We further anticipated CD14 in TG mice would be245
significantly higher than in the WT mice. We found246
microglia that were CD14 positive were not limited247
to activated microglia nor the Tg mice; furthermore,248
our data demonstrated the pro-inflammatory marker,249
CD14, increases with age in the ramified morphology 250
in the WT mice by 12 months of age (Fig. 2). 251
At 3 months of age, approximately 22% of 252
microglia counted co-localized with CD14 regardless 253
of strain; with a majority of those CD14 microglia 254
being in the ramified morphology (Tg = 72%, 255
WT = 84%). At 6 months, approximately 50% of 256
microglia counted were positive for CD14 in the 257
Tg mice. Of the CD14 microglia, approximately 258
60% were in an activated state, whereas in the 259
WT mice, approximately 66% of microglia counted 260
were CD14 positive and a majority of these (56%) 261
were ramified. By 12 months, CD14 in the Tg 262
mice remained at approximately 50% of microglia 263
counted; however, a majority (62%) of these were in 264
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Fig. 2. Representative CD14 and Iba1 IHC images from wildtype (WT) and APP/PS1 (TG) mice. Iba1 (red) ramified microglia were evident
at 3 months in both WT and TG mice, however, by 6 months microglial morphogy became more activated in TG mice especially in relation
to plaques (blue). CD14 (green) was prevelant by 6 months of age regardless of strain, with staining increasing at 12 months.
the ameboid/macrophage morphology. Conversely, at265
12 months in the WT mice, 81% of the microglia266
counted were positive for CD14, of which 86%267
were in the ramified morphology (see Table 1). Sta-268
tistical analysis revealed CD14 positive microglia269
in the Tg mice was most prominent in the amoe-270
boid/macrophage morphology at 12 months of age271
(p < 0.001). Further statistical analysis with a two-272
way ANOVA revealed that CD14 immunoreactivity273
without the factor of morphological subtypes demon-274
strated a significant interaction between age and275
strain (F(2,30) = 6.84, p = 0.0036; Fig. 3A). Tukey’s276
post-hoc tests showed that CD14 positive microglia277
was significantly upregulated in the Tg mice at 6278
months (p < 0.01; Fig. 3) and 12 months of age279
(p < 0.0001; Fig. 3) in comparison to the WT mice.280
Separating the microglia based on morphological281
subtype demonstrated significance between age and282
strain in the ramified (F(2,30) = 31.36, p < 0.0001;283
Fig. 3B), activated (F(2,30) = 33.66, p < 0.0001;284
Fig. 3D), and amoeboid/macrophage (F(2,30) = 15.66,285
p < 0.001; Fig. 3E) morphologies through a two-way286
ANOVA.287
Table 1
CD14 positive microglia in wild-type (WT) and APP/PS1 (TG)
mice at 3, 6, and 12 months of age. Numbers in brackets are Iba1
positive microglia counted
CD14 3 months 6 months 12 months
WT 56 (251) 152 (231) 211 (260)
TG 69 (303) 654 (1315) 741 (1490)
Further analysis via a Tukey’s post-hoc multiple 288
comparisons test demonstrated that there was a sig- 289
nificant downregulation of CD14 positive ramified 290
morphology in the Tg mice both 6 months (p < 0.001) 291
and 12 months of age (p < 0.0001) compared to con- 292
trol mice. CD14 positive colocalization in activated 293
microglia of Tg mice demonstrated a significant 294
downregulation at 6 months (p < 0.01) but then was 295
upregulated at 12 months (p < 0.0001). CD14 positive 296
amoeboid microglia in the APP/PS1 mice demon- 297
strated upregulation at both 6 months (p < 0.05) 298
and 12 months (p < 0.0001) when compared to WT 299
mice. A spatial analysis was also performed to deter- 300
mine the CD14 immunoreactivity of microglia at 301
plaque and non-plaque locations in the Tg mice. 302
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Fig. 3. Quantification of CD14 immunoreactivity. Representative high power image of CD14 immunohistochemistry staining in separate
channels and merged. Closed arrows denote colocalization of microglia and CD14 (A). CD14 expression without the factor of morphological
subtypes demonstrated a significant interaction between age and strain (F(2,30) = 6.84, p = 0.0036; B). Separating the microglia based on mor-
phological subtype demonstrated significance between age and strain in the ramified (F(2,30) = 31.36, p < 0.0001; C), activated (F(2,30) = 33.66,
p < 0.0001; D), and amoeboid (F(2,30) = 15.66, p < 0.001; E) morphologies through two-way ANOVA. The data demonstrated CD14 expres-
sion was more significantly associated to plaque depositions than the surrounding microglia at both 6 months (p < 0.05; Fig. 2F) and 12
months (p < 0.0001).
The data demonstrated CD14 immunoreactivity in303
amoeboid/macrophage microglia, which was more304
significantly associated to plaque depositions than305
the surrounding microglia at both 6 months (p < 0.05;306
Fig. 3F) and 12 months (p < 0.0001; Fig. 3F).307
CD40 is associated with pro-inflammatory proper-308
ties and previously has been shown to show no change309
in the normal aging process [26]. In the APP/PS1310
mouse model, we hypothesized that CD40 posi-311
tive microglia would increase within the activated312
morphology correlating to increase amyloid plaque313
deposition (Fig. 4). Through a two-way ANOVA,314
it was revealed that CD40 immunoreactivity in315
all microglial subtypes demonstrated a signifi- 316
cant interaction was found between age and strain 317
(F(2,30) = 15.86, p < 0.0001; Fig. 5). Further analysis 318
with Tukey’s post-hoc showed CD40 to be signifi- 319
cantly upregulated in the Tg mice at 12 months of age 320
(p < 0.0001; Fig. 5) compared to their age-matched 321
WT counterparts. 322
At 3 months of age, approximately 46% of 323
microglia counted co-localized with CD40 in the 324
Tg mice; with a majority (∼68%) of those CD40 325
microglia being in the ramified morphology. In WT 326
mice, approximately 38% of microglia at 3 months 327
colocalized with CD40, with a majority (∼56%) 328
Un
co
rre
cte
d A
uth
or
 P
ro
of
O.G. Holloway et al. / Plaque Associcated Changes to Microglial Phenotype & Morphology 7
Fig. 4. Representative immunohistochemical images of CD40 and Iba1. Ramfied Iba1 (red) microglia were evenly distributed throughout the
wildtype (WT) cortex, whereas Iba1 positive microglia in the APP/PS1 (TG) mice displayed a mixed morphology of activated and ramified.
At 6 months of age, CD40 colocalization with Iba1 was evident in TG mice which increased 12 months (closed arrows).
being in the ramified morphology. At 6 months,329
approximately 47% of microglia counted were pos-330
itive for CD40 in the Tg mice. Of the CD40331
microglia approximately 53% were in an activated332
state, whereas in the WT mice, approximately 78% of333
microglia counted were CD40 positive and a major-334
ity of these (60%) were ramified. By 12 months,335
CD40 in the Tg mice remained at approximately 65%336
of microglia counted; however, a majority (62%) of337
these were in the activated morphology. Conversely,338
at 12 months in the WT mice 89% of the microglia339
counted were positive for CD40, of which 56% were340
in the ramified morphology (see Table 2).341
A two-way ANOVA of positive CD40 staining342
found a significant interaction of age and strain in343
the ramified (F(2,30) = 13.39, p < 0.0001; Fig. 5C),344
activated (F(2,30) = 15.59, p < 0.0001; Fig. 5D), and345
amoeboid (F(2,30) = 66.06, p < 0.0001; Fig. 5E) mor-346
phologies when compared to control mice. Through347
Tukey’s post hoc analysis, the CD40 immunoreactiv-348
ity in ramified microglia was found to be significantly349
upregulated in the wild-type mice at 6 months350
(p < 0.05) and at 12 months (p < 0.0001) compared351
to the Tg mice. CD40 immunoreactivity in activated 352
microglia in the Tg mice was found to be signifi- 353
cantly upregulated at 12 months (p < 0.0001). CD40 354
immunoreactivity in amoeboid microglia was found 355
to be significantly increased in the Tg mice at 6 356
(p < 0.05) and 12 months (p < 0.0001). Overall, CD40 357
immunoreactivity was more prominent in the acti- 358
vated morphology compared to the other subtypes. 359
Further spatial analysis of all morphologies found 360
significant CD40 positive microglia associated with 361
plaques at 12 months (p < 0.001; Fig. 5F). 362
Anti-inflammatory markers CD16 and TREM1 363
were significantly increased in activated 364
microglia in the Tg mice 365
CD16 is associated with an immune regulatory 366
role. CD16 has previously been observed to increase 367
with normal aging, which was also evident in our 368
findings (Fig. 6) [27]. In the Tg we hypothe- 369
sized that CD16 would be increase in the activated 370
morphology of microglia correlating to increased 371
amyloid plaque deposition. Through a two-way 372
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Fig. 5. Quantification of CD40 immunoreactivity. Representative high power image of CD40 immunohistochemistry staining in separate
channels and merged. Closed arrows denote colocalization of Iba1 positive microglia and CD40 (A). Statistical analysis via two-way ANOVA
revealed CD40 expression in all microglial subtypes (B), with a significant interaction was found between age and strain (F(2,30) = 15.86,
p < 0.0001). CD40 colocalization with microglia in all morphologies, significance was found through a two-way ANOVA between interaction
and strain in the ramified (F(2,30) = 13.39, p < 0.0001; C), activated (F(2,30) = 15.59, p < 0.0001; D), and amoeboid (F(2,30) = 66.06, p < 0.0001;
E) morphologies when compared to wildtype mice. Spatial analysis of all morphologies found significant CD40 immunoreactivity with
microglia associated with plaques at 12 months (p < 0.001; F).
Table 2
CD40 positive microglia in wild-type (WT) and APP/PS1 (TG)
mice at 3, 6, and 12 months of age. Numbers in brackets are Iba1
positive microglia counted
CD40 3 months 6 months 12 months
WT 112 (298) 215 (275) 237 (293)
TG 133 (287) 244 (521) 714 (1103)
ANOVA, it was revealed that CD16 immunoreac-373
tivity, across microglial regardless of morphological374
subtypes demonstrated a non-significant interaction375
between age and strain (F(2,30) = 3.026, p = 0.0635;376
Fig. 7B). However, significance in CD16 immunore- 377
activity was found in the main effects of strain 378
(F(1,30) = 16.66, p = 0.0003) and age (F(2,30) = 14.00, 379
p < 0.0001). Through further analysis with Tukey’s 380
post-hoc, CD16 was found to be significantly upreg- 381
ulated in the APP/PS1 mice at 6 months of age 382
(p < 0.01) compared to age-matched control mice. 383
At 3 months of age, approximately 31% of 384
microglia counted co-localized with CD16 in the 385
Tg mice; with a majority (∼69%) of those CD16 386
microglia being in the activated morphology. In 387
WT mice, approximately 22% of microglia at 3 388
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Fig. 6. Representative immunohistochemical images of CD16 and Iba1. Ramfied Iba1 (red) microglia were evenly distributed throughout the
wildtype (WT) cortex, whereas Iba1 positive microglia in the APP/PS1 (TG) mice displayed a mixed morphology of activated and ramified.
CD16 (green) was evident from 3 months of age regardless of strain, with significant increases at 6 months in the both the WT and APP/PS1
(TG) mice. CD16 was still evident at 12 months in both strains.
months colocalized with CD16, with a majority389
(∼76%) being in the ramified morphology. At 6390
months, approximately 42% of microglia counted391
were positive for CD16 in the Tg mice. Of the CD16392
microglia approximately 74% were in an activated393
state, whereas in the WT mice, approximately 46% of394
microglia counted were CD16 positive and a major-395
ity of these (54%) were ramified. By 12 months,396
CD16 in the Tg mice remained at approximately 34%397
of microglia counted; however, a majority (53%) of398
these were in the activated morphology. Conversely,399
at 12 months in the WT mice, 62% of the microglia400
counted were positive for CD16, of which 59% were401
in the activated morphology (see Table 3).402
Separating CD16 positive microglia based on mor-403
phological subtype significance was found between404
age and strain in the ramified (F(2,30) = 3.705, p =405
0.0365; Fig. 7C), activated (F(2,30) = 3.593, p =406
0.0399; Fig. 7D), and amoeboid (F(2,30) = 15.06,407
p < 0.0001; Fig. 7E) morphologies through two-408
way ANOVA. Further multiple comparisons using409
Tukey’s post-hoc demonstrated significant positive410
CD16 in activated microglia at 6 months of age in 411
the Tg mice (p < 0.001) compared to controls. For 412
the amoeboid morphology, CD16 immunoreactivity 413
was significantly upregulated in the Tg mice at both 6 414
months (p < 0.001) and 12 months (p < 0.0001) com- 415
pared to WT mice. Overall, analyzing positive CD16 416
microglia between the morphologies, CD16 was most 417
prominent in the activated morphology at 6 months. 418
Further spatial analysis was also performed of posi- 419
tive CD16 microglia at plaque and non-plaque sites. 420
it was determined that CD16 was significantly upreg- 421
ulated at both 6 months (p < 0.05) and 12 months 422
(p < 0.001; Fig. 7F) at plaque locations. 423
TREM2 is associated with anti-inflammatory 424
properties and previously has been shown to have 425
increased expression in normal aging [28]. TREM2 426
variants have been identified as a risk factor for AD, 427
with recent studies reporting an increase in the AD 428
brain [28]. In the Tg mice we hypothesized that posi- 429
tive TREM2 microglia would increase in the activated 430
morphology correlating to increase amyloid plaque 431
deposition (Fig. 8). 432
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Fig. 7. Quantification of CD16 immunoreactivity. Representative high power image of CD16 immunohistochemistry staining in separate
channels and merged. Closed arrows denote colocalization of Iba1 positive microglia and CD16 (A). Statistical analysis via a two-way
ANOVA revealed CD16 immunoreactivity, not accounting for morphological subtypes demonstrated a non-significant interaction between
age and strain (F(2,30) = 3.026, p = 0.0635; B). Separating CD16 positive microglia based on morphological subtype significance was found
between age and strain in the ramified (F(2,30) = 3.705, p = 0.0365; C), activated (F(2,30)=3.593, p = 0.0399; D),and amoeboid (F(2,30) = 15.06,
p < 0.0001; E) morphologies through two-way ANOVA. Spatial analysis was also performed of CD16+ immunoreactive microglia at plaque
and non-plaque sites. it was determined that CD16 expression was significantly upregulated at both 6 months (p < 0.05) and 12 months
(p < 0.001) at plaque locations (F).
Table 3
CD16 positive microglia in wild-type (WT) and APP/PS1 (TG)
mice at 3, 6, and 12 months of age. Numbers in brackets are Iba1
positive microglia counted
CD16 3 months 6 months 12 months
WT 50 (233) 121 (265) 170 (275)
TG 73 (233) 326 (771) 323 (944)
At 3 months of age, approximately 15% of433
microglia counted co-localized with TREM2 in the434
Tg mice; with a majority (∼69%) of those TREM2435
microglia being in the ramified morphology. In WT436
mice, approximately 36% of microglia at 3 months 437
colocalized with TREM2, with a majority (∼78%) 438
being in the ramified morphology. At 6 months, 439
approximately 55% of microglia counted were pos- 440
itive for TREM2 in the Tg mice. Of the TREM2 441
microglia approximately 67% were in an activated 442
state, whereas in the WT mice, approximately 48% 443
of microglia counted were TREM2 positive and a 444
majority of these (76%) were ramified. By 12 months, 445
TREM2 in the Tg mice remained at approximately 446
50% of microglia counted; however, a majority 447
(60%) of these were in the activated morphology. 448
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Fig. 8. Representative immunohistochemical images of TREM2 and Iba1. Ramfied Iba1 (red) microglia were evenly distributed throughout
the wildtype (WT) cortex, whereas Iba1 positive microglia in the APP/PS1 (TG) mice displayed a mixed morphology of activated and
ramified. TREM2 (green) staining was more pronounced at 6 months in both the WT mice and TG mice. However, at 12 months TREM2
was most evident in TG mice.
Table 4
TREM2 positive microglia in wild-type (WT) and APP/PS1 (TG)
mice at 3, 6, and 12 months of age. Numbers in brackets are Iba1
positive microglia counted
TREM2 3 months 6 months 12 months
WT 101 (278) 129 (269) 157 (293)
TG 36 (242) 244 (447) 469 (946)
Conversely, at 12 months in the WT mice, 54% of449
the microglia counted were positive for TREM2, of450
which 52% were in the activated morphology (see451
Table 4).452
Through two-way ANOVA analysis of TREM2453
immunoreactivity, a significant interaction was found454
between age and strain in all morphological subtypes455
(F(2,30) = 10.75, p = 0.0003; Fig. 9B). Through further456
analysis with Tukey’s post-hoc, TREM2 immunore-457
activity was found to be significantly upregulated458
in the AD mice at 12 months of age (p < 0.0001)459
compared to control mice. When analyzing the mor-460
phology of TREM2 positive microglia through a461
two-way ANOVA, a significant interaction between462
age and strain was found in activated (F(2,30) = 6.244, 463
p = 0.0054; Fig. 9D) and amoeboid (F(2,30) = 26.71, 464
p < 0.0001; Fig. 9E) morphologies when compared to 465
controls. Further multiple comparisons using Tukey’s 466
post-hoc demonstrated significant downregulation of 467
TREM2 immunoreactivity in the ramified morphol- 468
ogy at 6 months (p < 0.05; Fig. 9C) compared to 469
controls. TREM2 immunoreactivity in the activated 470
morphology microglia was significantly downregu- 471
lated at 6 months (p < 0.05) but then upregulated at 472
12 months (p < 0.001). Amoeboid/macrophage-like 473
microglia, TREM2 immunoreactivity found signifi- 474
cant upregulation in the Tg mice at both 6 months 475
(p < 0.05) and 12 months (p < 0.0001). Overall, when 476
comparing TREM2 in all morphological subtypes, 477
TREM2 immunoreactivity in the APP/PS1 mice 478
was most prominent at both 6 and 12 months in 479
the activated morphology. Further spatial analy- 480
sis of all microglial morphology subtypes revealed 481
TREM2 positive microglia were significantly asso- 482
ciated with plaque sites at 12 (p < 0.001; Fig. 9F) 483
months of age. 484
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Fig. 9. Quantification of TREM2 immunoreactivity. Representative high power image of TREM2 immunohistochemistry staining in separate
channels and merged. Closed arrows denote colocalization of Iba1 positive microglia and CD16 (A). Analysis via a two-way ANOVA revealed
a significant interaction of TREM2 expression between age and strain in all morphological subtypes (F(2,30) = 10.75, p = 0.0003; B). Using
Tukey’s post-hoc transgenic mice demonstrated a significant downregulation of TREM2 in the ramified morphology at 6 months (p < 0.05;
C) compared to controls. When breaking down morphology TREM2 expression through a two-way ANOVA, a significant interaction
between age and strain was found in activated (F(2,30) = 6.244, p = 0.0054; D) and amoeboid (F(2,30) = 26.71, p < 0.0001; (E)) morphologies
when compared to controls. Further spatial analysis of all microglial morphology subtypes revealed TREM2 expression of all microglial
morphologies was significantly associated with plaque sites at 12 months of age (p < 0.001; F).
DISCUSSION485
Our study investigated different microglial mor-486
phologies and their expression of cell surface markers487
to develop a greater understanding of the microglial488
phenotype in AD. Our data suggests that both pro-489
and anti-inflammatory cell surface marker increase490
with mounting plaque deposition at 3, 6, and 12491
months in an APP/PS1 mouse model. Both inflamma-492
tory phenotypes were associated with the activated493
morphological subtype; however, CD14 expression494
was associated with the amoeboid morphology. The 495
authors acknowledge that solely using immunohisto- 496
chemistry to examine microglia in AD is a limitation 497
of this study. However, by collecting the tissue for 498
immunohistochemistry it enabled spatial examina- 499
tion of microglia in regions close to plaques and 500
the capacity to visualize phenotype of microglia to 501
morphology and plaque size. By collecting tissue 502
for molecular techniques such as western blotting or 503
PCR, the capacity to determine microglial specific 504
morphology and the location in relation to plaques is 505
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lost. Further studies which incorporate these molec-506
ular techniques to confirm immunohistochemistry507
results are required. This study has important impli-508
cations for understanding microglial inflammation in509
AD, adding further evidence for a push for phenotypic510
analysis to move away from discrete characterization.511
Morphometric changes were associated with512
increasing amyloidosis513
The morphometric aspect of this study investigated514
the change in ramified, activated and amoeboid mor-515
phologies. To classify morphology of microglia we516
used parameters from our previously published stud-517
ies [11–17]. A limitation of this is the subjective518
nature of classification and the lack of morphometri-519
cal details, such as soma size, number and length of520
processes and branch points (see [29, 30]). Nonethe-521
less, data suggests that with increasing amyloidosis,522
microglia undergo a distinct morphological shift.523
In the Tg mice, ramified microglia were observed524
to decrease at each time point, which was par-525
ticularly obvious around plaques. The decrease of526
ramified microglia may be indicative of parenchyma527
surveillance loss, instead moving toward defensive528
morphologies. In our age-matched controls there529
was also a decrease in ramified microglia, though530
not to the extent seen in the Tg mice. These data531
mirror reports from other models, where reduced532
microglial arborizations were observed [29]. The de-533
ramification of Tg mice may be reflective of disease534
progression alone [31].535
The activated microglial morphology increased536
significantly in the APP/PS1 mouse model. Inversely537
to the ramified morphology, an increase of activated538
microglia was observed at both 6 and 12 months,539
compared to control mice. This morphology was540
mostly associated with the increase pro-inflammatory541
profiles, suggesting a role in becoming reactive542
to homeostatic changes phenotype. However, this543
does not exclude other morphologies from being544
able to express inflammatory markers as evident545
in this study. Similarly, to activated, amoeboid546
microglia/macrophages also increased at 6 and 12547
months of age, particularly at plaque sites. It remains548
unclear whether these morphological changes are549
a sign of degeneration to the disease process or550
instigated for a specific role. However, studies have551
demonstrated a physical role for the rapid increase of552
microglia at plaque sites. The upsurge of activated and553
amoeboid microglia/macrophages that are directly554
associated, encapsulating the plaques in a sense, has555
been shown to have role in limiting plaque expansion 556
[32, 33]. The behavior of microglia morphological 557
shifts is arguably heavily dependent on the stage of 558
disease. 559
The increased distortion of microglial morpholo- 560
gies has been previously hypothesized to be indictive 561
of dysregulation and the last step before senescence 562
[34]. This is known as the glial cell dysregula- 563
tion hypothesis of AD, whereby the increasingly 564
toxic environment renders microglial defensive func- 565
tions and ultimately perpetuates the disease process 566
through abnormal expression of cytokine, reactive 567
species, and other mediators [34]. This suggests that 568
even though this study saw an increase of cell surface 569
markers associated with pro- and anti-inflammatory 570
properties, it does not mean that their downstream 571
effects are functional. The morphological shifts 572
observed in this study therefore could align with a 573
theory of microglial dysregulation in neurodegener- 574
ation, where clumping of swollen microglia and loss 575
of homogenous tissue distribution occurs [34]. A lim- 576
itation of the current study is that the APP/PS1 mouse 577
is only modelling one pathological hallmark of AD 578
and potentially we are only visualizing a small com- 579
ponent of the microglial damage. Further research 580
is therefore required with the combination of neu- 581
rofibrillary tangles, which could advance microglial 582
dysregulation. 583
AD microglia present mixed inflammation 584
Our study demonstrated that microglia are 585
heterogenic in the immunoreactivity of cell sur- 586
face markers. Inflammatory markers are therefore 587
not fitting to determine microglial modality nor 588
morphology alone, as the markers used are both 589
beneficial and deleterious to AD pathology. We 590
suggest that microglia express a mixture or pro- 591
anti-inflammatory cell markers that potentially 592
are not functioning appropriately. Previously used 593
nomenclatures, including M1 and M2, have been 594
too simplistic to describe microglial responses, 595
as it does not encompass the theory of microglial 596
dysregulation. The incorporation of other microglial 597
surface markers would be advantageous in future 598
studies. In accordance with the microglial com- 599
munity, the emerging agreeance is that microglia 600
are heterogeneous in their phenotypic profile [35]. 601
We investigated cell surface expression of CD16, 602
TREM2, CD14, and CD40. CD16 and TREM2 are 603
associated with anti-inflammatory properties and 604
have been used to define microglial populations in 605
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health and disease models [6, 28, 36], whereas CD14606
and CD40 are typically assigned pro-inflammatory607
properties and thus have been used to determine dele-608
terious microglia [6, 37]. This study reports mixed609
inflammation across 3, 6, and 12 months in APP/PS1610
mice, with the number of microglia that were positive611
for the pro-inflammatory markers, CD14 and CD40,612
being slightly elevated at 6 and 12 months compared613
to the anti-inflammatory markers TREM2 and CD16.614
However, the proportion of microglia which were615
positive for CD14, CD40, or TREM2 was similar616
∼50% in APP/PS1 mice. The proportion of microglia617
positive for CD16 remained at ∼30% in APP/PS1618
mice compared to ∼60% in wild-type, suggesting619
the potential dysregulation of anti-inflammatory620
markers is an indicator of disease status and more621
research is required to fully elucidate this point.622
Anti-inflammatory cell surface markers: CD16623
and TREM2624
Anti-inflammation in AD has previously been sug-625
gested to be dampened or to disrepair through the626
production of pro-inflammation [38]. Our data agrees627
with this notion that anti-inflammation is dampened628
or dysregulated, as their corresponding cell surface629
markers are not decreasing overtime. To the best of630
our knowledge there have been no previous stud-631
ies looking at a relationship between CD16 and632
TREM2 marker immunoreactivity in microglial mor-633
phological subsets, nor has their immunoreactivity634
over multiple time points in an APP/PS1 mouse635
model been quantified. CD16 is characterized by636
ligation of immunoglobulin Fc gamma receptors637
(FcRs), resulting in downregulated expression of638
IL-12 and increased IL-10 and HLA-DR expression,639
while TREM2 is associated with a wide array of640
functions in the healthy CNS, such as survival, activa-641
tion, proliferation, phagocytosis, cell maturation, and642
inflammation [39]. TREM2 has also been shown to643
inhibit inflammation through downregulation of PI3644
K/AKT and NF-kB signaling [40].645
CD16 immunoreactivity was found to be increased646
at 6 months in activated morphology, whereas647
TREM2 was significantly higher in activated mor-648
phologies at both 6 and 12 months. Human studies649
of microglia CD16 are few, with one noting an650
early AD stage increase of CD16 [41], and another651
showing a decrease in late stage AD [42]. We also652
demonstrate an increase of CD16 and TREM in ram-653
ified microglia in WT mice at 6 and 12 months of654
age. This fits into the research showing that normal655
ageing phenotypes show an increase in inflammatory 656
markers [43]. Even though TREM2 is associated with 657
anti-inflammatory profiles, contemporary literature is 658
finding an increase of TREM2 immunoreactivity in 659
human AD brains [28, 44]. 660
Recent literature found that TREM2 variants are 661
in fact a risk factor for early-onset AD [45]. TREM2 662
mediates the switch from homeostatic to a neurode- 663
generative microglia phenotype in APP/PS1 mice 664
through the APOE pathway [46]. This contradicts the 665
use of markers being used to phenotype microglia 666
into discrete, pro- or anti-inflammatory phenotypes. 667
Our data further indicates microglia activation does 668
not adhere solely to a pro- or anti-inflammatory 669
framework. Potential reasons for the differences in 670
anti-inflammatory microglia being upregulated and 671
downregulated at different time points would most 672
likely be due to functionality and disease-specific 673
expressions. We recognize that though we see the 674
immunoreactivity, whether this expression is func- 675
tional was not investigated at this point. 676
Pro-inflammatory markers: CD14 and CD40 677
Pro-inflammation is widely associated with end- 678
stage of disease [38]. Our study looked at the 679
pro-inflammatory markers, CD40 and CD14. To our 680
knowledge, very few studies have looked at these 681
markers over time to increasing plaque load, nor 682
have studied them in association with any spe- 683
cific morphology. However, both markers having 684
been identified in post-mortem tissue of AD patients 685
[5, 47]. CD40 and its corresponding CD40 ligands 686
play a critical role in the activation of microglial and 687
inflammatory marker expression. The expression of 688
CD40/CD40L has been reported to be altered in AD 689
patients [48]. The induction of CD40 on microglial 690
occurs in the presence of soluble forms of A, sug- 691
gesting an early role of CD40 in disease progression. 692
CD14 is associated with pro-inflammation and thus 693
an M1 phenotype; however, functionally CD14 is 694
more diverse, as it also plays a role in phagocytic 695
function [48]. 696
As detection techniques become more sophis- 697
ticated, more reports are providing evidence that 698
microglia are never resting [49–51]. The ramified 699
morphology is constantly surveying the microenvi- 700
ronment. Indeed, ramified microglia undergo various 701
changes to respond to stimuli to move into what is 702
traditionally referred to as an activated state [14, 49]. 703
In this state they are hypothesized to secrete pro- 704
inflammatory cytokines and express inflammatory 705
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markers. However, little is known about whether706
microglia continue to express these markers as they707
return from their deramified “activated” state back to708
their ramified “resting” morphology. Here, we show709
that ramified microglia do indeed express an array710
of markers that have traditionally been assigned711
to deramified states, particularly CD14. This is in712
line with evidence that ramified microglia have the713
capacity to phagocytose. It also adds to the growing714
body of evidence that microglia may become primed715
through aging and after exposure to insults, disease716
or infections and never fully return to the naı¨ve rami-717
fied state [14, 16, 52, 53]. Indeed it has been reported718
tha microglia are primed from middle age [54].719
Previous literature investigating the potential role720
of CD14 in APP/PS1 mice has reported decreased721
plaque burden when CD14 is knocked out [7]. Fur-722
ther, CD14 knockout mice had increased expression723
of genes encoding for proinflammatory cytokines and724
decreased alternative activation markers of microglia,725
Fizz1 and Ym1. Taken together with the data from the726
current study, further investigation into the inflamma-727
tory pathways mediated by CD14, especially in AD,728
is warranted as these data suggest CD14 is a critical729
regulator of the microglial inflammatory response to730
amyloidosis.731
CONCLUSION732
Our results demonstrated that microglia cell sur-733
face expression present in a mixed inflammatory734
profile corresponding with increasing plaque depo-735
sition. Furthermore, these distinctive profiles were736
localized to plaque sites. Our data indicate microglial737
inflammatory profiles are on a continuum throughout738
disease progression, with the balance being pushed739
towards pro-inflammatory markers. Further, morpho-740
logical analysis indicated a characteristic pattern in741
AD progression compared to wildtype, with the acti-742
vated morphology being associated with increased743
mixed inflammation. This research highlights the744
intricacies of microglial expression and morphologi-745
cal shifts that occur in AD.746
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